Abstracts Archive - Page 1128 of 2607 - ACR Meeting Abstracts

Abstract Number: 2820 • 2019 ACR/ARP Annual Meeting
Calcium/ Calmodulin – Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production
Milena Vukelic¹, Nobuya Yoshida ², Masataka Umeda ³, Seo Yeon Orite ³, Rhea Bhargava ³, Michihito Kono ⁴, Irina Gavanescu-Stockton ³, Ryo Hisada ³ and George Tsokos ², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is disease characterized by an imbalance between pro-inflammatory (such as Th1 and Th17) and regulatory cells (Tregs). Th1 and Th17…
Abstract Number: 2821 • 2019 ACR/ARP Annual Meeting
Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease
Cory Perugino¹, Naoki Kaneko ², Jesper Kers ³, Takashi Maehara ², Hamid Mattoo ⁴, Hang Liu ⁵, Vinay Mahajan ⁵, Musie Ghebremichael ⁵, Hugues Allard-Chamard ⁵, Yesim Tuncay ⁵, Emanuel Della Torre ⁶, Zachary Wallace ¹, Lloyd Liang ¹, Sydney Montesi ⁷, John Stone ⁸ and Shiv Pillai ⁹, ¹Massachusetts General Hospital, Boston, ²Kyushu University, Fukuoka, Japan, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Sanofi, Cambridge, ⁵Ragon Institute of MGH, MTI and Harvard, Cambridge, ⁶Hospital San Raffaele, milan, Italy, ⁷Massachusetts General Hospital, Boston, MA, ⁸Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁹Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: In IgG4-related disease (IgG4-RD), both activated B cells and CD4+ cytotoxic T lymphocytes (CD4+CTLs) expand clonally, accumulate in tissues, likely recognize distinct epitopes on…
Abstract Number: 2824 • 2019 ACR/ARP Annual Meeting
Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)
Navraj Nagra¹, Danielle Robinson ², Antonella Delmestri ¹, Stephanie Dakin ¹, Sarah Snelling ¹, Andrew Carr ¹ and Daniel Prieto-Alhambra ¹, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: The microbiome and specific bacterial triggers have been hypothesised to be involved in the pathogenesis of Rheumatoid Arthritis (RA) and RA flares. Antibiotic usage…
Abstract Number: 2825 • 2019 ACR/ARP Annual Meeting
Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Michael George¹, Joshua Baker ², Lang Chen ³, Qufei Wu ², Fenglong Xie ⁴, Huifeng Yun ³ and Jeffrey Curtis ³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham
Background/Purpose: Glucocorticoids are recommended as short-term bridging therapy in patients with rheumatoid arthritis (RA), but as many as 30-40% of patients remain on glucocorticoids chronically.…
Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Ajinkya Pawar ¹, Rishi Desai ¹, Nileesa Gautam ¹ and Seoyoung C. Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
Abstract Number: 2827 • 2019 ACR/ARP Annual Meeting
Weight Fluctuation and Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis
Joshua Baker¹, George Reed ² and Joel Kremer ³, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona Research Foundation, Waltham, MA, ³Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Fluctuations in weight (weight cycling) occur in rheumatoid arthritis (RA) in association with severe disease features and comorbidity. In the general population, weight fluctuation…
Abstract Number: 2828 • 2019 ACR/ARP Annual Meeting
Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams
Edmond Ramly ¹, Douglas White ², Amanda Perez ¹ and Christie Bartels¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Gundersen Health System, Onalaska
Background/Purpose: Despite recognition that rheumatoid arthritis (RA) accelerates cardiovascular disease (CVD) and hypertension impacts 50% of RA patients, up to 50% lack blood pressure (BP)…
Abstract Number: 2829 • 2019 ACR/ARP Annual Meeting
Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk
Shivani Garg¹, Betty Chewning ², Karen Hansen ³, Beth Martin ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW - School of Pharmacy, Madison, Madison, ³UW Madison, Madison
Background/Purpose: Up to 83% of patients with SLE are nonadherent to hydroxychloroquine (HCQ) which results in a 36% higher risk of renal failure, and 8-fold…
Abstract Number: 2830 • 2019 ACR/ARP Annual Meeting
Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study
Zachary Wallace¹, Tyler Harkness ¹, Xiaoqing Fu ¹, John Stone ², Hyon K. Choi ³ and Rochelle Walensky ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior authorizations (PA) are commonly required by health payers as cost-containment strategies for expensive medications, including infused biologics. In rheumatology, these medications are frequently…
Abstract Number: 2831 • 2019 ACR/ARP Annual Meeting
Cracks in Your Referral Process? Find Your Sustainable Solution Here
Sheetal Vora¹, Amanda Moyer ², Lynn Kalhagen ², Anna Sherrod ², Thomas Griffin ², Kristen Corcoran ², Sarah Mabus ² and Talia Buitrago ², ¹Atrium Health, Charolotte, ²Atrium Health, Charlotte
Background/Purpose: Early diagnosis for rheumatic conditions is crucial for children to achieve the best functional outcomes. Access to care is difficult due to the volume…
Abstract Number: 2832 • 2019 ACR/ARP Annual Meeting
Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target
Lucy Liu¹, Sonam Choden ², Jennifer Barton ³, Puneet Bajaj ⁴, Christie Bartels ⁵, Maria Danila ⁶, Elizabeth Wahl ⁷, Kimberly Reiter ⁸, Joann Zell ⁹, Christina Downey, MD ¹⁰, Elena Weinstein ¹¹, Gabriela Schmajuk ² and Jinoos Yazdany ¹², ¹UCSF, Oakland, CA, ²UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ³VA Portland Health Care System & Oregon Health & Science University, Portland, OR, ⁴UT Southwestern, Dallas, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷VA Puget Sound, Seattle, WA, ⁸Albuquerque VA Medical Center, University of NM School of Medicine, Albuquerque, NM, ⁹Denver Health, Denver, CO, ¹⁰Loma Linda University Medical Center, Loma LInda, CA, ¹¹University of Colorado Department of Rheumatology, Denver, CO, ¹²UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A treat to target (T2T) approach in managing RA can improve patient outcomes. A key component to T2T is establishing personalized treatment targets through…
Abstract Number: 2833 • 2019 ACR/ARP Annual Meeting
Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients
Elke Mathijssen¹, Johanna Vriezekolk ² and Bart van den Bemt ², ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: International guidelines for rheumatoid arthritis (RA) treatment emphasize that all treatment decisions should be made through a shared decision making (SDM) process between clinicians…
Abstract Number: 2834 • 2019 ACR/ARP Annual Meeting
Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study
Michael Fralick¹, Sarah Chen ², Elisabetta Patorno ³ and Seoyoung C. Kim ⁴, ¹Mount Sinai Hospital, University of Toronto, Toronto, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Harvard University, Boston, ⁴Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: Hyperuricemia is common in patients with type 2 diabetes mellitus and is associated with an increased risk of gout. Sodium-glucose cotransporter 2 (SGLT2) inhibitors,…
Abstract Number: 2835 • 2019 ACR/ARP Annual Meeting
A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout
Niamh Fanning¹, Ruth Topless ², Christopher Frampton ¹, Murray Cadzow ², Mary Wallace ³, Nicola Dalbeth ⁴, Tony Merriman ⁵ and Lisa Stamp ⁶, ¹University of Otago, Christchurch, Christchurch, New Zealand, ²University of Otago, Otago, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Auckland, Auckland, New Zealand, ⁵University of Otago, Birmingham, AL, ⁶University of Otago, Christchurch, Christchurch, Canterbury, New Zealand
Background/Purpose: Current understanding of why the urate lowering effect of allopurinol varies among individuals with gout is limited. The rs2231142 (Q141K) variant of ABCG2 is…
Abstract Number: 2836 • 2019 ACR/ARP Annual Meeting
Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank
Vicky Tai¹, Ravi Narang ¹, Greg Gamble ¹, Lisa Stamp ², Tony Merriman ³ and Nicola Dalbeth ¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ³University of Otago, Birmingham, AL
Background/Purpose: Both serum urate-associated genetic variants and body mass index (BMI) are associated with gout risk. The aim of this study was to systematically examine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].